218 related articles for article (PubMed ID: 34783018)
1. Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen.
Kariyawasam DST; D'Silva AM; Herbert K; Howells J; Carey K; Kandula T; Farrar MA; Lin CS
J Physiol; 2022 Jan; 600(1):95-109. PubMed ID: 34783018
[TBL] [Abstract][Full Text] [Related]
2. Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy.
Farrar MA; Vucic S; Lin CS; Park SB; Johnston HM; du Sart D; Bostock H; Kiernan MC
Brain; 2011 Nov; 134(Pt 11):3185-97. PubMed ID: 21926101
[TBL] [Abstract][Full Text] [Related]
3. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
[TBL] [Abstract][Full Text] [Related]
4. Peripheral nerve maturation and excitability properties from early childhood: Comparison of motor and sensory nerves.
Kandula T; Park SB; Carey KA; Lin CS; Farrar MA
Clin Neurophysiol; 2020 Oct; 131(10):2452-2459. PubMed ID: 32829292
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
7. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
8. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
9. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
11. Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability.
Farrar MA; Park SB; Lin CS; Kiernan MC
J Physiol; 2013 Jan; 591(1):273-86. PubMed ID: 23006483
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
13. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
15. Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen.
Schneider C; Wassermann MK; Grether NB; Fink GR; Wunderlich G; Lehmann HC
Eur J Neurol; 2021 Sep; 28(9):3022-3029. PubMed ID: 34216082
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
17. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen treatment of older children and adults with spinal muscular atrophy.
Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
